655 related articles for article (PubMed ID: 17579499)
1. CNS complications of breast cancer: current and emerging treatment options.
Kaal EC; Vecht CJ
CNS Drugs; 2007; 21(7):559-79. PubMed ID: 17579499
[TBL] [Abstract][Full Text] [Related]
2. Management of brain metastases.
Soffietti R; Rudā R; Mutani R
J Neurol; 2002 Oct; 249(10):1357-69. PubMed ID: 12382150
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of central nervous system metastases from breast cancer.
Chang EL; Lo S
Oncologist; 2003; 8(5):398-410. PubMed ID: 14530493
[TBL] [Abstract][Full Text] [Related]
5. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
7. DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer.
Borm KJ; Behzadi ST; Hörner-Rieber J; Krug D; Baumann R; Corradini S; Duma MN; Dunst J; Fastner G; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Matuschek C; Piroth MD; Schmeel LC; Souchon R; Strnad V; Budach W; Combs SE;
Strahlenther Onkol; 2024 Apr; 200(4):259-275. PubMed ID: 38488902
[TBL] [Abstract][Full Text] [Related]
8. Leptomeningeal Metastases.
Graber JJ; Kesari S
Curr Treat Options Oncol; 2018 Jan; 19(1):3. PubMed ID: 29362920
[TBL] [Abstract][Full Text] [Related]
9. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
10. CNS metastases in breast cancer.
Lin NU; Bellon JR; Winer EP
J Clin Oncol; 2004 Sep; 22(17):3608-17. PubMed ID: 15337811
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases.
Jung TY; Chung WK; Oh IJ
Clin Neurol Neurosurg; 2014 Apr; 119():80-3. PubMed ID: 24635931
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy.
Mix M; Elmarzouky R; O'Connor T; Plunkett R; Prasad D
J Neurosurg; 2016 Dec; 125(Suppl 1):26-30. PubMed ID: 27903186
[TBL] [Abstract][Full Text] [Related]
13. γ knife radiosurgery of brain metastasis from breast cancer.
Padovani L; Muracciole X; Régis J
Prog Neurol Surg; 2012; 25():156-62. PubMed ID: 22236677
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Figura NB; Rizk VT; Mohammadi H; Evernden B; Mokhtari S; Yu HM; Robinson TJ; Etame AB; Tran ND; Liu J; Washington I; Diaz R; Czerniecki BJ; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2019 Jun; 175(3):781-788. PubMed ID: 30859348
[TBL] [Abstract][Full Text] [Related]
15. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
16. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.
Ho VK; Gijtenbeek JM; Brandsma D; Beerepoot LV; Sonke GS; van der Heiden-van der Loo M
Eur J Cancer; 2015 Nov; 51(17):2508-16. PubMed ID: 26277099
[TBL] [Abstract][Full Text] [Related]
17. Malignant melanoma brain metastases: Treatment results and prognostic factors--a single-center retrospective study.
Ostheimer C; Bormann C; Fiedler E; Marsch W; Vordermark D
Int J Oncol; 2015; 46(6):2439-48. PubMed ID: 25891163
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
